Kilama Wen
African Malaria Network Trust, Tanzania Commission for Science and Technology Building, Ali Hassan Mwinyi Road, Dar es Salaam, Tanzania.
Acta Trop. 2009 Nov;112 Suppl 1:S91-S101. doi: 10.1016/j.actatropica.2009.08.014. Epub 2009 Aug 15.
Although Africa's health research capacity is still weak, African R&D institutions are contributing immensely to the development of health policies, guidelines and products essential for diagnosis, treatment, prevention and control of Africa's leading health problems. In order to increase Africa's contributions, all health research stakeholders should participate in setting health research priorities and agenda, followed by establishing health research networks and consortia, holistic capacity strengthening, and gathering of baseline data. The evaluation of candidate tools, and the research preceding it, must abide by international scientific and ethical standards, and must involve institutional and national regulatory authorities. The funding of product development and product availability in Africa benefits from national governments, bilateral, multilateral, and philanthropic agencies. When a trial is over poses many social and ethical issues, and not infrequently existing guidelines may not be adequate. Mechanisms for making products available in resource constrained countries are presented, as are problems relating to manufacturing, markets and procurement. So are obligations to trial and research communities. The paper concludes by outlining the obligations of each stakeholder, in order to make research products readily available in resource constrained settings.
尽管非洲的卫生研究能力仍然薄弱,但非洲的研发机构正在为制定诊断、治疗、预防和控制非洲主要卫生问题所需的卫生政策、指南和产品做出巨大贡献。为了增加非洲的贡献,所有卫生研究利益相关者应参与确定卫生研究的优先事项和议程,随后建立卫生研究网络和联盟,进行全面的能力建设,并收集基线数据。对候选工具及其之前的研究进行评估,必须遵守国际科学和伦理标准,并且必须有机构和国家监管当局的参与。非洲产品开发和产品供应的资金来源于各国政府、双边、多边和慈善机构。试验结束时会引发许多社会和伦理问题,而且现有指南往往可能并不充分。本文介绍了在资源有限国家提供产品的机制,以及与制造、市场和采购相关的问题。还介绍了对试验和研究团体的义务。本文最后概述了每个利益相关者的义务,以便在资源有限的环境中使研究产品易于获取。